Results day
Aspen results
Every recent Aspen results day: what the company reported, how the share moved that day, and when it reports next.
JSE: APN · Pharmacy & health retail
- Next results
- Not announced yet
- Last results day
- 03 Sept 2026
- Share move that day
- +6.5%
In plain wordsThe latest numbers.
In the year to June 2025, Aspen reported revenue of R43.4bn, down 3.0% on the year before, and earnings of -R1.1bn (down 124.6%).
Its results for the year to June 2026, published on 3 September 2026, are not in these figures yet; the headlines below cover them.
Since 2022, revenue has grown by an average of 3.9% a year.
Over the last twelve months it ran an operating margin of -5.9%, with 7.6% of revenue kept as profit.
Its latest reported period showed revenue down 16.9% on the same period a year earlier.
It paid R2.32 a share in dividends over the last year, a yield of 1.5% at today’s price.
It holds more cash (R16.0bn) than debt (R15.6bn).
On its last results day, 3 September 2026, the share rose 6.5%.
Written from the company’s reported figures as Yahoo Finance carries them, which can lag a new set of results by a few weeks.
Who runs itThe Aspen team.
- Stephen Bradley Saad BCom, CA(SA)Group CEO & Executive Director
- Sean M. CapazorioGroup CFO & Executive Director
- Lorraine HillGroup Chief Operations Officer
- Michael Guy Attridge B.Com., CA(SA)Group Chief Advisor
- Raeesa KhanGroup Company Secretary & Chief of Staff
- Samer KassemChief Executive Officer of Aspen Global Incorporated
As listed by Yahoo Finance, which can lag changes the company has announced. The company’s own website has the current line-up.
Results dayResults days
- Thursday, 03 September 2026Share move that day +6.5%
- FY 2027 targets over ZAR 9bn EBITDA and 50%+ NHEPS growth, led by steriles and GLP-1s
- EBITDA and NHEPS surged on efficiency gains and APAC divestment, with GLP-1s fueling outlook
- Wednesday, 02 September 2026Share move that day -7.3%
- 28% NHEPS growth, strong EBITDA, APAC divestment, and robust cash flow drive improved outlook
- South African drugmaker Aspen's earnings rise 22%
- Tuesday, 03 March 2026Share move that day +0.4%
- Commercial Pharmaceuticals growth and APAC divestment drive improved outlook despite lower earnings
- Aspen Pharmacare Reports HY HEPS Of 417,4 Cents
- African drugmaker Aspen reports 21% earnings decline due to one-off costs
- Wednesday, 11 February 2026Share move that day -0.2%
- Earnings fell on restructuring costs, but core pharma growth and lower net debt support FY outlook
APNRevenue and earnings by year
| Year | Revenue | vs year before | Earnings | vs year before |
|---|---|---|---|---|
| 2022 | R38.6bn | – | R6.5bn | – |
| 2023 | R40.7bn | +5.4% | R5.2bn | -19.4% |
| 2024 | R44.7bn | +9.8% | R4.4bn | -15.8% |
| 2025 | R43.4bn | -3.0% | -R1.1bn | -124.6% |
Results season: who reports next
Headlines from Reuters and Quartr via TradingView; prices and yearly numbers from Yahoo Finance. Results dates can move, and companies confirm them on SENS. Information, not advice.
The Monday briefCommerce, in your inbox.
Every Monday: last week’s moves in JSE commerce, your own shares, and the results and numbers due this week. Free, and you can unsubscribe any time.
We don’t take outside money, but we always like talking markets and commerce.
For media, research and partnership questions, send us an email.
